Our CEO, Prof. Edward Hæggström was featured in the PODD 2021 newsletter where he discussed the exciting developments at Nanoform and the market trends driving the innovation. Edward also delved into the collaborations and partnerships adding value to Nanoform’s nanoparticle engineering technologies.
Pharma Integrates 2021
Video 1: “Are you in or out?” panel discussion at Pharma Integrates 2021
Our VP of Business Development, Nathalie Huther, PhD, MRSC, shared her insights into how the pandemic has affected pharma outsourcing and what it means for the future at Pharma Integrates 2021.
Video 2: ’Forecasting Pharma’s Future” panel discussion at Pharma Integrates 2021
Our Commercial Insight Officer, Jamie Unwin, shared his perspective on the future of Pharma and patient-centric technological innovation at Pharma Integrates 2021.
Partnerships in Drug Delivery (PODD) 2021
Video 1: Nanotechnology Fireside Chat at Partnerships in Drug Delivery (PODD) 2021
Our CEO, Prof. Edward Hæggström, was delighted to join a fireside chat at PODD with Shawn Davies, Head of Drug Delivery, Biopharmaceuticals Development, AstraZeneca – a long term partner of Nanoform – to discuss the potential of nanoscale medicines and delivery devices to benefit patients.
Video 2: “Small is transformative: nanoparticle solutions for drug delivery innovation” at Partnerships in Drug Delivery (PODD) 2021
Our VP of US Business Development, Eric Peter, delved into the human trial results for the world’s first nanoformed drug at PODD 2021. He also discussed the ongoing industry collaborations investigating how nanoparticle engineering can facilitate drug delivery innovation to ultimately benefit patients.
Our VP of US Business Development, Chris Worrall, hosted a webinar “Tailored API Nanoparticles: How Powerful Can Small Be?” in partnership with the American Association of Pharmaceutical Scientists (AAPS). Tune in to discover the benefits of tailoring nanoparticles for the development of patient-centric medicines.
In the July 2021 issue of ONDrugDelivery, Niklas Sandler and Thomas West consider the technological advances in nanoparticle engineering that can improve the bioavailability and delivery of oral therapeutics.
Poster presentation : ‘’Small is powerful : Comparison of approaches to tackle poor solubility of drugs’’ at AAPS PharmSci 360 2021
Nanoform Director of Pharmaceutical Development, Satu Lakio, presented a poster to AAPS on the effectiveness of Nanoformed particles compared clinically against two commercially approved products.
Video presentation: Demonstrating the Power of Controlled-Expansion scCO2 Applied to Drug Development at AAPS PharmSci 360 2021
Watch Nanoform Director of Pharmaceutical Development, Satu Lakio, present to AAPS how effective Nanoformed particles could be when compared clinically against two commercially approved products.
“Nanoformers, Particles in Disguise! – Illuminating the future of Pharma with STARMAP®.” PharmaTech Integrates 2021
Nanoform were attendees at Life Science Integrates’ and the Medicines Manufacturing Innovation Centre’s one-day event, PharmaTech Integrates. Our Commercial Insights Officer, Jamie Unwin shared his thoughts on the “Revolution not evolution of Biologics production” panel. The session explored how the industry can step up to meet patient need and market demand by streamlining, enhancing and integrating upstream and downstream biological and vaccine production.
David McCelland from Life Science Knowledge Hub interviews Jamie Unwin, our Commercial Insights Officer at Nanoform. They discuss Nanoform’s growth and their ambition of touching the lives of billion patients. Jamie also emphasises the importance of their data-driven approach and how AI is transforming the approach to drug development.
The Nanoform team attended the American DDF Summit (Drug Delivery & Formulation) with Commercial Insights Officer Jamie Unwin chairing a panel discussion titled “Preparing for Patient-Centric Drug Development Regulations”. The session explored the topic of patient centric drug design and how patient centricity can influence the drug development process.
A year on from Nanoform’s IPO in June 2020, we have made trailblazing progress. In this video, we share how we’ve transformed to reach key milestones, from the launch of our biologics technology to the completion of our first-in-human trial of a nanoformed drug candidate.
We were pleased to host a session, “Overcoming Drug Development Challenges with Nanotechnology,” at the first ever CPhI Discover virtual event. Nanoform CCO Christian Jones, FRSC, Nanoform Science & Technology Team Leader Elisabetta Micelotta, and experts from Johnson Matthey and Quotient Sciences shared insights into the power of sparse-data AI in drug development and the collaborative studies investigating the performance of our CESS® technology.
Watch it here to learn more about AI-guided nanoparticle engineering in Pharma, from early drug development to clinic.
Our CCO, Christian Jones, FRSC, joined the Bio Integrates panel discussion “Start with an end in mind” on Thursday, May 20th, 2021. The panel explored the importance of connecting with patients to make sure that products are designed around the patient’s needs.
Overcoming Drug Development Challenges with Nanotechnology: Piroxicam, a commercially available non-steroidal anti-inflammatory drug, was nanoformed as a model compound to demonstrate the potential benefits of our CESS(R) nanoforming technology for improving solubility, dissolution and in vivo absorption.
We were excited to showcase the results from our collaboration with Johnson Matthey in our webinar with The Nanomed Zone: “How CESS® technology stacks up against the competition: the smaller, the better!”.
Watch the presentation to learn how CESS® nanoparticles of a model compound have been found to exhibit improved dissolution performance relative to all other industry standard approaches tested, including spray drying.
Our Director of Pharmaceutical Development, Satu Lakio, gave a presentation at the 12th Global DDF Summit (Drug Delivery & Formulation) covering “Unique Nanoforming Technology for Poorly Soluble APIs by Nanoform”.
Our Head of AI, Prof. Jukka Corander joined a panel discussion at BIO-Europe Spring 2021 on “Big data & AI: applications in the real world”. Watch the video to find out out how Sparse Data AI & specifically STARMAP® can transform healthcare.
We achieved a number of milestones in 2020, check out the highlights here!